A Multinational Investigation of the Impact of Subcutaneous Sumatriptan
This report describes the design, methods and clinical results of a prospective sequential multinational (5 countries) study conducted to evaluate the effects of subcutaneous sumatriptan on health-related quality of life, workplace productivity, clinical parameter5 and patit:lli satisfaction.
Adult patients with moderate to severe migraine initially received customary therapy for migraine episodes for 12 weeks, followed by 24 weeks’ treatment with self-administered subcutaneous sumatriptan 6mg. Demographic, baseline, health-related quality of life and patient satisfaction rating data were collected during visits to the clinic. Data relating to migraine symptoms, migraine therapy, work productivity and non-work activity time were collected on diary cards filled out by the patients.
749 patients were recruited to the study and 637 received at least I dose of sumatriptan. Overall, 75.5% of migraines were successfully treated within 2 hours with sumatriptan compared with 3 I.9% with customary therapy; 36% of patients reported complete relief at 2 hours with sumatriptan treatment compared with 1% of patients receiving customary therapy. 69% of patients successfully treated 70% of their migraines with sumatriptan within 2 hours, compared with 12% of patients with customary therapy. No serious adverse events were reported; 50% of patients reported an adverse event during the 12-week customary therapy phase and 89% of patients during the 24-week sumatriptan phase.
These clinical results, which are consistent with those reported in randomised blinded studies of subcutaneous sumatriptan, suggest that relief of migraine symptoms occurs more often, and in less time, in patients receiving subcutaneous sumatriptan rather than customary therapy as their primary medication.
Unable to display preview. Download preview PDF.
- 1.De Lissovoy G Lazaru SS. The economic cost of migraine. Nuerology 1994; 44 Suppl. 4: 56–62Google Scholar
- 2.Greiner DL Addy SN. Sumatriptan use in a large group-model maintenance organization. Am J Health Syst Pharm 1940: 53:633–8Google Scholar
- 4.Clouse JC, Osterhaus JT. Healthcare resource use and costs asssociated with migraine in a managed healthcare setting. Ann Pharma cother 1994; 28: 659–64Google Scholar
- 5.Cull RE, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ 1992; 2: 103–15Google Scholar
- 8.Prevalence of chronic migraine headaches–United Slales, 1980-1989. MMWR Morh Mortal Wkly Rep 1991; 40: 331Google Scholar
- 10.The Subcutaneous Sumatriptan International Study Group.Treatment of migraine attacks with sumatriptan.N Engl J Med 1991; 325: 316–21Google Scholar
- 15.Jhingren P. Cady RK. Ruhino J. et al. Improvements in healthrelated quality of life with sumatriptan treatment for migraine.J Fam Pract 1996; 42 (1): 36–42Google Scholar
- 16.Bouchard J. Cortelli P. et al. A multinational investigation of the impact of subcutaneous sumatriptan. II: health related quality of life. Pharmaco Economics 1997; 11 Suppl.1: 24–34Google Scholar
- 19.Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headachedisorders. cranial neuralgias and facial pain Cephalalgia1988; 8 Suppl. 7: 1–96Google Scholar
- 20.Ware JE. SF-36 Health Survey Manual and Interpretation Guide. Boston. MA: New England Medical Center. 1993Google Scholar
- 21.Sherbourne CD. The MOS-36-ltem Short-Form Health Survey ISF-36). Med Care 1992; 30: 474–83Google Scholar
- 22.Miller DW. Kirchdoerfer LJ. Shepherd MD. et al. A disease specific instrument to measure quality of life effects attributableto migraine. Poster presentation at the Health ServicesResearch Association 10th Annual Meeting; Jun 27-29. 1993:Washington DCGoogle Scholar
- 25.Migraine: clinical. therapeutic. conceptual and researchaspects. London: Chapman & Hall. 1987: 3–30Google Scholar
- 27.Chazot G. Boureau F. Emile I. et al. Comparison of sumatriptan with usual acute treatment of migraine. Cephalalgia 1993; 13Suppl. 13: 162Google Scholar
- 28.Miller DW. Osterhaus JT. Hirsch JD. et al. Quality of life assessment among migraineurs treated with sumatriptan: preliminary findings. 35th Annual Scientific Meeting for theAmerican Association for the Study of Headache (AASH). Headache 1993; 33 (8): 278Google Scholar